PRAX

PRAX is actively defying the 'Caution' macro regime by absorbing a Q4 EPS miss (-$3.50 vs -$3.09) to trade higher, a classic 'Bad News Bought' signal. The bullish thesis is anchored by the confirmation of two NDA submissions (Ulixacaltamide & Relutrigine) and a fortress balance sheet (~$1.5B cash) that de-risks operations through 2028. While the broad market frets over geopolitical war drums, PRAX is trading on idiosyncratic regulatory progress, validating the 'Rocket Ships' divergence noted by the CIO.